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AbsTrACT
Objectives to estimate the prevalence of, and 
describe risk factors for, genital warts (gWs) in the 
British population, following the introduction of 
the bivalent (human papillomavirus (HPV)-16/18) 
vaccination programme in girls, and prior to the switch 
to quadrivalent (HPV-6/11/16/18) vaccine (offering direct 
protection against gWs) and compare this with gW 
diagnoses in the prevaccination era.
Methods natsal-3, a probability sample survey in 
Britain, conducted in 2010–2012, interviewed 9902 
men and women aged 16–44. natsal-2, conducted in 
1999–2001, surveyed 11 161 men and women aged 
16–44. Both surveys collected data on sexual behaviour 
and sexually transmitted infection diagnoses using 
computer-assisted interview methods.
results in natsal-3, 3.8% and 4.6% of sexually 
experienced men and women reported ever having 
a diagnosis of gWs, with 1.3% of men and 1.7% of 
woman reporting a gWs diagnosis in the past 5 years. 
gWs were strongly associated with increasing partner 
numbers and condomless sex. Diagnoses were more 
frequent in men who have sex with men (MSM) (11.6% 
ever, 3.3% past 5 years) and in women reporting sex 
with women (10.8% ever, 3.6% past 5 years). in the age 
group who were eligible for vaccination at the time of 
natsal-3 (16–20 years), a similar proportion of same-
aged women reported a history of gWs in natsal-2 
(1.9%, 1.1–3.4) and natsal-3 (2.6%, 1.5–4.4).
Conclusions these data provide essential parameters 
for mathematical models that inform cost-effectiveness 
analyses of HPV vaccination programmes. there was no 
evidence of population protection against gWs conferred 
by the bivalent vaccine. even with vaccination of 
adolescent boys, vaccination should be offered to MSM 
attending sexual health clinics.
InTrOduCTIOn
Genital warts (GWs) are the most common viral 
sexually transmitted infection (STI) diagnosed 
among genitourinary medicine clinic (GUM) 
attendees in the UK1 and globally.2 The diagnosis 
and treatment of GWs also has associated indi-
vidual and healthcare costs: in 2008, the annual 
expenditure on GWs in England was estimated at 
£16.8 million,3 and each episode is estimated to 
have a QALY loss equivalent to 6.6 days of healthy 
life lost.4
In 2008, the UK began a human papillomavirus 
(HPV) immunisation programme in adolescent 
girls (aged 11–12 years, with catch-up to 17 years), 
initially using the bivalent vaccine which protects 
against HPV types 16 and 18, the most frequent 
causes of cervical cancer. In 2012, the programme 
switched to quadrivalent HPV vaccine which addi-
tionally protects against HPV types 6 and 11, which 
are responsible for over 90% of cases of GWs.5
A recent systematic review6 of the effectiveness 
of the quadrivalent vaccine, following 10 years of 
real-world experience, reported that, as early as 
2 years after starting a vaccination programme in 
girls, and with high coverage such as in Australia 
and Denmark, there was a rapid and marked reduc-
tion in the incidence of GWs among women eligible 
for vaccination and some benefit conferred to simi-
lar-aged heterosexual men.7 Reductions in GWs in 
men who have sex with men (MSM) have been, as 
expected, less evident.8 In England, surveillance 
data from GUM clinics have shown an unexpected 
reduction in diagnoses of GWs between 2009 and 
2011,9 particularly in women in the age groups 
offered bivalent vaccination and, to a lesser extent, 
in similar-aged heterosexual men, and this has 
continued to 2014.10 This ecological observation, 
together with findings of moderate efficacy against 
some low-risk HPV types in a posthoc analysis of 
the PATRICIA (Papilloma TRIal against Cancer In 
young Adults) trial of the bivalent vaccine,11 has led 
to a hypothesis that the bivalent vaccine may confer 
a modest cross-protective effect against GWs.
The availability of population-based compar-
ison data from the prevaccination era is important 
to demonstrate population impact.6 Furthermore, 
it is important to monitor the prevalence of GWs 
in different subgroups, to ensure that vaccination 
programmes are widely accessed, reach those at 
greatest risk and reduce health inequalities. For 
Britain, the National Surveys of Sexual Attitudes 
and Lifestyles (Natsal) are able to capture the 
population burden of STIs and link this to detailed 
behavioural information. This includes people who 
access services for testing, diagnosis and treatment 
including, but not limited to sexual health (GUM) 
clinics, which are the main contributors to STI 
surveillance. The timings of the Natsal surveys 
allow estimation of the population effects of HPV 
vaccination: Natsal-2 was conducted in 1999–2001 
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Table 1 Reported diagnoses of genital warts, ever, in the past 5 years and in the past year, in British men and women aged 16–44*
16–19 20–24 25–34 35–44 Total aged 16–44
% 95% CI % 95% CI % 95% CI % 95% CI % 95% CI
Men 
Denom. (unwt, wt)† 578, 370 785, 620 1432, 1284 775, 1367 3570, 3642
Genital warts 
  Ever 0.2% (<0.1 to 0.9) 1.8% (1.0 to 3.3) 4.7% (3.6 to 6.1) 4.9% (3.4 to 6.8) 3.8% (3.0 to 4.7)
  Past 5 years 0.2% (<0.1 to 0.9) 1.8% (1.0 to 3.3) 2.0% (1.3 to 3.0) 0.6% (0.3 to 1.5) 1.3% (0.9 to 1.7)
  Past year 0.2% (<0.1 to 0.9) 0.4% (0.1 to 1.4) 0.4% (0.1 to 1.1) 0.2% (<0.1 to 1.3) 0.3% (0.2 to 0.6)
Women 
Denom. (unwt, wt)† 667, 341 1059, 621 2362, 1304 1169, 1397 5257, 3662
Genital warts 
  Ever 1.5% (0.7 to 2.9) 5.0% (3.6 to 7.0) 4.8% (3.9 to 6.0) 4.9% (3.8 to 6.4) 4.6% (4.0 to 5.3)
  Past 5 years 1.1% (0.6 to 2.3) 4.3% (2.9 to 6.3) 1.6% (1.1 to 2.4) 0.6% (0.3 to 1.3) 1.7% (1.3 to 2.1)
  Past year 0.7% (0.3 to 1.7) 1.2% (0.6 to 2.5) 0.1% (<0.1 to 0.6) <0.1% (<0.1 to 0.4) 0.3% (0.2 to 0.6)
*Data from Natsal-3 2010–2012.
†Denominators are those with 1+partner ever.
prior to the introduction of any HPV vaccination, with Natsal-3 
in 2010–2012 taking place after the introduction of bivalent 
vaccination (but prior to the switch to quadrivalent vaccine).
This paper reports the prevalence of reported diagnoses of, 
and risk factors for, GWs in the British population in Natsal-3. 
We examine changes in reported prevalence of GW diagnoses 
between the birth cohorts eligible for vaccination in Natsal-3, 
with those of equivalent age in the prevaccination era in 
Natsal-2, to assess whether there is population-based evidence 
of cross-protection against GWs.
MATErIAls And METhOds
Participants and procedures
Natsal-3 interviewed 15 162 men and women aged 16–74 in 
2010-2012. Details of the study methods have been described 
previously.12 Briefly, we used a multistage, clustered, stratified 
probability sample design. The response rate was 57.7%. Partic-
ipants were interviewed through a combination of face-to-face 
computer-assisted personal interview and computer-assisted 
self-interview for the more sensitive questions, including on their 
experience of STI diagnoses. Participants were asked if they had 
ever been told by a doctor or other healthcare professional that 
they had any of a list of different STIs, including GWs, and if so, 
when they were last diagnosed with GWs. Natsal-2 (undertaken in 
1999–2001 surveyed 11 161 men and women aged 16–44, with a 
response rate of 65.4%.13 The surveys use similar methodology to 
allow comparison over time. HPV catch-up vaccination coverage 
in Natsal-3 participants was 61.5%.14 Vaccine uptake varied by 
school year at eligibility, with 72.9% of women eligible at 14 years 
reporting having received all three doses, compared with only 
50.6% of women eligible at 17 years.15
statistical analysis
Of the 3809 men and 5510 women aged 16–44 years in Natsal-3, 
we included sexually experienced participants with information 
on GW history (3570 men (93.7%) and 5257 women (95.4%)) 
in the main analysis. Analysis accounts for the stratification, clus-
tering and weighting of the sample. We describe the prevalence 
of reported history of GWs over different time periods by age. In 
those reporting at least one partner in the past 5 years (of either 
gender), we stratify this according to experience of same-sex sex 
during this timeframe. Age-adjusted odds ratios (aORs) are calcu-
lated for the association between key behavioural risk factors 
and a history of GWs in the past 5 years. Data for comparison 
between Natsal-2 (4267 men and 5869 women) and Natsal-3 
were available for sexually experienced men and women aged 
16–44 years. We describe the prevalence of reported history 
of GWs in the age group of the birth cohorts in Natsal-3 who 
would have been eligible for vaccination (aged 16–20 years) and 
present a prevalence ratio with 95% CIs. Data were analysed 
using Stata (V.14.1).
Ethics
Natsal-3 was granted ethical approval by the Oxfordshire 
Research Ethics Committee A (Reference: 09/H0604/27). 
Natsal-2 obtained ethical approval from University College 
Hospital, North Thames Multicentre and all local research ethics 
committees in Britain.
rEsulTs
Using data from Natsal-3 (2010–2012), table 1 shows how the 
proportion of the population reporting a diagnosis of GWs varied 
by age and gender. Overall, 3.8% of sexually experienced men and 
4.6% of sexually experienced women aged 16–44 had ever had a 
diagnosis of GWs. Ever diagnosis increased with age, plateauing at 
around 5% at age 25 in men and age 20 in women. In total, 1.3% 
of men and 1.7% of women had a diagnosis in the past 5 years, 
with 0.3% of men and women reporting a diagnosis in the past 
year.
Diagnoses were more frequent in MSM (11.6% ever and 
3.3% past 5 years) than men who reported exclusively having 
sex with women (3.6% ever and 1.2% past 5 years) (table 2). 
Similarly, diagnoses were more frequent in women reporting sex 
with women (WSW) (10.8% ever and 3.6% past 5 years) than 
in women who reported exclusively having sex with men (4.3% 
and 1.6%, respectively).
A diagnosis of GWs was associated with age, but there were no 
significant associations with ethnicity, area-level deprivation or 
educational status (data not shown). Figure 1 shows behavioural 
factors associated with a diagnosis of GWs in the past 5 years 
in those with one or more partner in this timeframe. For both 
men and women, a warts diagnosis was strongly associated with 
increasing partner numbers and condomless sex.
Those reporting a same-sex partner in the past 5 years were 
also more likely to report a history of GWs (aOR 2.66 (0.94–
7.50) in men and 1.99 (1.00–3.94) in women); however, this 
effect was no longer significant after adjusting further for partner 
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Table 2 Reported diagnoses of genital warts in those aged 16–44 years by same-sex behaviour in the past 5 years*
Men Women
MsEW† MsM† WsEM† WsW†
% 95% CI % 95% CI % 95% CI % 95% CI
Denom. (unwt, wt)‡ 3377, 3471 137, 116 4881, 3430 304, 189
Genital warts 
  Ever 3.6% (2.9–4.4) 11.6% (5.7–22.1) 4.3% (3.6–5.0) 10.8% (7.2–15.8)
  Past 5 years 1.2% (0.9–1.7) 3.3% (1.2–8.3) 1.6% (1.2–2.0) 3.6% (2.0–6.5)
  Past 1 year 0.3% (0.1–0.6) 0.4% (0.0–2.5) 0.3% (0.2–0.6) 0.7% (0.2–2.6)
*Data from Natsal-3 2010–2012.
†MSEW (men who have sex exclusively with women); MSM (men who have sex with men, including men who have sex with men and women).
‡Denominators are those with 1+partner in the past 5 years.
WSEM, women who have sex exclusively with men; WSW, women who have sex with women, including women who have sex with men and women.
Figure 1 Factors associated with a diagnosis of genital warts in the past 5 years, in men and women aged 16–44.* See separate jpg file. *Data 
from Natsal-3. denominators are those with 1+partner in the past 5 years. Age-adjusted ORs and 95% CIs.
numbers (adjusted OR 0.95 (0.29–3.13) in men and 0.92 (0.46–
1.84) in women).
In Natsal-2, data were only available on a history of GWs 
ever. This was reported in 3.7% (3.1%–4.3%) of men and 4.2% 
(3.7%–4.8%) of women aged 16–44 years, very similar propor-
tions to those reported a decade later in Natsal-3. Specifically, 
in women in the birth cohorts who would have been eligible 
for vaccination in Natsal-3 (16–20 years at time of interview), 
a similar proportion of same-aged women reported a history of 
GWs in Natsal-2 (13/556, weighted prevalence 1.9%, 1.1–3.4) 
and Natsal-3 (21/870, weighted prevalence 2.6%, 1.5–4.4), 
with a prevalence ratio, comparing Natsal-3 to Natsal-2, of 1.35 
(95% CI: 0.61 to 2.98).
dIsCussIOn
Repeated cross-sectional population-based decennial surveys, 
such as Natsal, can provide baseline and postintervention 
estimates of prevalence, behaviour and uptake of services for 
national programmes. These are vital to monitor impact, model 
cost-effectiveness and guide decision-making on interventions, 
including vaccination strategies. Natsal data complements 
surveillance but is also able to provide important parameters 
for modelling HPV transmission dynamics that cannot be ascer-
tained from clinic-based data, such as lifetime GW diagnoses and 
detailed sexual behaviour.
A diagnosis of GW was associated with markers of more risky 
sexual behaviours, similar to those for other STIs, including 
high-risk HPV infection.14 GWs were less common in hetero-
sexual men and women in the general population, compared 
with men and women reporting same-sex behaviour. During the 
same time period as Natsal-3, a cross-sectional survey of ~500 
MSM attending a London GUM clinic was undertaken.16 In 
this clinic-attending population of MSM, nearly one-third had 
a previous diagnosis of GWs ever (30.3%), 1 in 10 had a GWs 
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diagnosis in the past year (9.8%) and in many cases they had had 
more than one episode.17 Our finding is consistent with knowl-
edge that MSM have a higher incidence of HPV infection and 
related disease.18 This knowledge, along with the expectation that 
MSM will benefit less from herd protection from the vaccination 
of women, informed the Joint Committee on Vaccination and 
Immunisation’s (JCVI) advice in 2016 that quadrivalent vaccina-
tion should be offered to MSM attending sexual health and HIV 
clinics, as a cost-effective intervention.19 Following this advice, 
a pilot of HPV vaccination for MSM attending sexual health 
and HIV clinics across England was introduced in summer 2016, 
with similar vaccination programmes introduced nationally in 
Wales (since April 2017)20 and Scotland (since July 2017).21 The 
pilot showed feasibility and acceptability (45.5% recorded first 
dose uptake) and a national HPV vaccination programme for 
MSM (up to and including 45 years of age) is being rolled-out 
from April 2018.22 The recommendation to offer vaccination 
up to this age is based on the knowledge that while the vaccine 
may be more effective in those without previous HPV exposure 
(who are likely to be younger), the majority of MSM attending 
clinics have not been infected with all HPV-types in the vaccine16 
and high-risk sexual behaviour, which is not restricted to young 
MSM, may result in repeated exposure.
Of note is that the prevalence estimates of ever having a 
diagnosis of GWs in MSM and WSW in the general population 
were similar at ~11%. The numbers of women who have sex 
exclusively with women in Natsal are very small, and the higher 
prevalence in WSW is likely to be in women having sex with 
both men and women. WSW have increased risk of STIs, higher 
partner numbers and other high-risk behaviours23 but the higher 
odds of GWs in WSW was no longer significant after adjusting 
for partner numbers. Nevertheless, given the high prevalence of 
GWs as well as lower uptake of cervical screening,15 it is impor-
tant that WSW are included in health promotion messages and 
that vaccination coverage is high in this group. Women reporting 
more than five partners were at even higher risk (figure 1). This 
supports mop-up vaccination in these women if they attend 
sexual health services while in the eligible age group, if they had 
missed one or more doses in the routine programme.
Using data from Natsal-2 and Natsal-3, we have previously 
shown an early indication of population-based effectiveness of 
the bivalent HPV vaccine in women in the age groups eligible for 
vaccination, with a ~50% reduction seen in the prevalence of 
HPV-16/18 in 18–20 year olds, but no observed change in preva-
lences of cross-protective types or in women aged 21–44.14 24 We 
have also previously reported that the prevalence of HPV-6/11 
in urine in women in the age group eligible for vaccination had 
not reduced significantly (9.5% in Natsal-2 vs 8.9% in Natsal-3, 
an age-adjusted prevalence ratio of 0.91 (0.44–1.89)).24 25 Like-
wise, in this paper, we found no change in the reporting of GW 
diagnoses following introduction of bivalent vaccination.
Our findings concur with the lack of protection against GWs 
observed in bivalent vaccine-immunised women in a number of 
studies26–28 and with the finding of no reduction in HPV-6 or 
HPV-11 infection in England29 or Scotland.30 Together, these 
data provide some evidence to refute the hypothesis of the 
HPV-16/18 vaccine conferring a cross-protective effect against 
HPV-6/11 and GWs. It is, however, possible that the timing 
of Natsal-3 relative to the start of the vaccination programme 
means that it was too soon to detect an effect on GWs and low 
risk HPV types, particularly since catch-up uptake was ~60% 
(but early enough to ascertain the greater direct effect on 
HPV-16/18).14 Small numbers may also have resulted in insuf-
ficient power to detect a significant difference in the prevalence 
ratio. Reductions in GWs were seen in the surveillance data by 
2011: possible reasons for this should have generated the same 
effects in Natsal-3, with the exception of changes in service use 
or other artefacts and measurement errors (when looking at 
diagnosis trends) in the surveillance data.
This paper presents data from Natsal-3, prior to the switch to 
quadrivalent vaccine. Based on data from other countries and 
that in the UK, there has already been high coverage of quad-
rivalent vaccine in girls for 5 years, large reductions in popu-
lation HPV-6/11 prevalence, and in diagnoses of GWs in both 
women and men, are already expected. Indeed, this is the case: 
in 2017, the rate of first episode GWs diagnoses among females 
aged 15–17 attending specialist sexual health services was 89% 
lower compared with 2009, with a decline of 70% in same aged 
heterosexual males over this time period, suggesting substantial 
herd protection.31 The impact of selective vaccination of MSM 
attending GUM/HIV clinics is expected to become evident in 
due course, as the vaccination programme started more recently 
and uptake is opportunistic and so will likely accrue more grad-
ually. Following the recent JCVI recommendation to extend the 
adolescent girls programme to boys,32 even further reductions, 
in a shorter timeframe, are to be expected. As discussed above, 
even with a vaccination programme that includes adolescent 
boys, there remains a case for continuing to offer vaccination to 
MSM attending sexual health clinics up to age 45.19 In addition 
to the high burden of infection and disease, a large proportion 
of MSM attending clinics may not have been born in the UK 
(>50% in the London study),16 including those from countries 
without a vaccination programme.
Cost-effectiveness analyses will continue to be needed to 
inform the UK HPV immunisation programme, for example, 
as new vaccines enter the market. Updating and extending this 
evidence is therefore helpful to reduce error and uncertainty 
within such analyses. These data may also be informative for 
other service and treatment planning, for example in countries 
considering introduction of, or changes to, a HPV vaccination 
programme. Further real-world evaluation of the impact of HPV 
vaccination on GWs should include monitoring in sexual health 
clinics, as part of routine surveillance and in stand-alone research 
studies, complemented by population-based surveys.
Key messages
 ► In the British population, 3.8% of sexually experienced 
men and 4.6% of sexually experienced women aged 16–44 
reported ever having a diagnosis of genital warts (GWs).
 ► GWs were more common in men and women reporting 
same-sex behaviour (11% ever diagnosed with GWs).
 ► There was no evidence of the bivalent vaccine conferring a 
cross-protective effect against GWs.
 ► Cost-effectiveness analyses, and real-world evaluation, will 
continue to be needed to inform UK human papillomavirus 
(HPV) immunisation policy, as changes are made to the 
vaccination programme (eg, vaccinating boys) and new 
vaccines enter the market (eg, nonavalent HPV vaccine).
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